Monkey Growth Hormone (GH) Receptor Gene Expression
EVIDENCE FOR TWO MECHANISMS FOR THE GENERATION OF THE GH BINDING PROTEIN*

(Received for publication, January 24, 1997, and in revised form, April 7, 1997)

Jean-François Martini Dagger §, Alain Pezet §, Charles Y. Guezennec , Marc Edery , Marie-Catherine Postel-Vinay and Paul A. Kelly par

From INSERM Unité 344, Endocrinologie Moléculaire, Faculté de Médecine Necker-Enfants Malades, 156 rue de Vaugirard, 75730 Paris Cedex 15, France and the  Département de Physiologie Systémique, CERMA, Base d'Essais en Vol, 91228 Brétigny-sur-Orge Cedex, France

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

The growth hormone receptor (GHR) cDNA was cloned from the liver of Rhesus macaque using polymerase chain reaction. As deduced from the nucleotide sequence, the mature GHR is a protein of 620 amino acids which presents 94.1% identity with the human receptor. The monkey GHR (mkGHR) expressed in 293 cells presented the expected specificity for a primate GHR and was able to transduce a transcriptional effect of GH. Human GH was able to activate tyrosine phosphorylation of both the tyrosine kinase JAK2 and the receptor in 293 cells co-transfected with mkGHR and JAK2 cDNAs. The GH binding protein (GHBP), the soluble short form of the GHR, was also present in monkey serum. Expression of the GHR cDNA in eucaryotic cells indicated that the GHBP can be produced by proteolytic cleavage of the membrane receptor. Northern blot analysis of GHR gene expression in different tissues allowed us to identify three different transcripts of 5.0 and 2.8 kilobase pairs and a smaller one of 1.7 kilobase pairs which could encode a GHBP. Rapid amplification of cDNA extremities (3'-RACE-polymerase chain reaction) was used to identify a cDNA encoding a protein in which the transmembrane and cytoplasmic domains of the receptor are substituted by a short sequence of 9 amino acids. This transcript was present in various tissues and could encode a GHBP as well, suggesting for the first time that two different mechanisms can coexist for the generation of the GHBP: proteolytic cleavage of the membrane receptor and a specific mRNA produced by alternative splicing.


INTRODUCTION

Growth hormone (GH)1 has a variety of biological effects in a large number of target tissues, particularly metabolic and growth effects on skeleton and soft tissues (1). GH actions at the cellular level, such as mitogenic effects (2, 3), insulin-like and anti-insulinic metabolic effects (4), as well as gene regulating actions (5-7), are mediated by receptors which belong to the same family as the prolactin (PRL) and many cytokine/hematopoietin receptors (8).

In many species including man, only the liver GH receptor (GHR) has been well characterized (9, 10). The rabbit liver GHR was purified to homogeneity and sequenced, and the cDNA encoding the GHR was cloned first in rabbit and subsequently in man (11), which permitted study of the expression of the GHR gene in many tissues (12, 13).

Some molecular events following the binding of GH to its receptor have been identified: dimerization of the GHR is induced (14) and initiates the association with a tyrosine kinase of the JAK family, followed by a cascade of protein phosphorylations, including the JAK2 kinase and the receptor itself (15). Moreover, transcriptional activation by the GHR has been determined by co-transfecting the promoter of a GH-responsive gene coupled to a reporter gene along with the cDNA of rat GHR (16) or of rabbit GHR (17). These transcriptional effects of GH involved signal transducers and activators of transcription (STATs) factors, and it has been shown that GH is able to activate the tyrosine phosphorylation of STAT1, STAT3, and STAT5 (18). Furthermore, several alternative signaling pathways have been identified to be induced by the activated GHR, such as stimulation and tyrosine phosphorylation of mitogen-activated protein kinase (19), and activation of voltage-dependent Ca2+ channels (20).

In addition to the membrane GHR, a soluble GH-binding protein (GHBP) has been identified in serum (21, 22). In rabbit, the amino acid sequences of the GHBP and of the extracellular domain of the membrane receptor are identical (11, 23). Two separate mechanisms have been proposed for the genesis of the GHBP. In mice and rats, two distinct mRNAs of 4.5 and 1.5 kb encode the full-length membrane receptor and the GHBP, respectively. In these species, the transmembrane region of the receptor has been replaced by a short hydrophilic tail (24, 25). In man, rabbit and several other species, the major mRNA transcript is ~4.5 kb as detected by Northern blot analysis; it has been proposed that GHBP results from proteolytic cleavage of the membrane-bound receptor. The release of GHBP was first demonstrated in the medium of IM-9 cells (26). More recently, direct evidence of the production of GHBP in cultured medium of cells transfected with the cDNA encoding the rabbit GHR has been presented (27).

In monkeys, GH has been purified (28), its primary structure identified (29) and its cDNA was cloned many years later (30). This hormone is 96% identical to human GH. The tissue distribution of the monkey GHR has been studied by ligand binding (31) but was not well characterized because of low expression of the GHR in most tissues. The only effect of GH studied in monkeys is the preservation of bone mass in hypogonadal females treated with recombinant human GH (32).

Although the human GHR cDNA was cloned several years ago, experiments using the full-length human cDNA have been impeded by difficulties such as growth of bacterial clones and altered specificity of expressed receptors, as reported by several authors (3, 11). We sought to clone another primate (Rhesus macaque) GHR cDNA for the development of tools to study signal transduction pathways. Evidence that two different mechanisms could coexist to generate the GHBP has been obtained in monkey.


EXPERIMENTAL PROCEDURES

Materials

Recombinant human GH was kindly provided by Serono-Ares Laboratories (Geneva, Switzerland), recombinant bovine GH by Dr. W. Baumbach (American Cyanamid Co., Princeton, NJ) (Ref. 9450-1-7), and recombinant human PRL by Dr. J. Martial (University of Liege, Belgium).

Animals

All tissues were obtained immediately after death from two adult male Rhesus macaque (8 and 9 years old) killed according to procedures recommended by the Panel on Euthanasia of the French Health Ministry. Tissues were frozen in liquid nitrogen and stored at -80 °C until used. Serum samples were of young and old adult male Rhesus macaque from the breeding of the Centre d'Etude et de Recherche en Médecine Aérospatiale, Brétigny-sur-Orge, France.

RNA Preparation

The preparation of RNA was carried out according to the acidic phenol/chloroform method (33). The recovery of total RNA was measured by spectrophotometer (Beckman DU-64, Beckman) at 260 nm. Some aliquots were loaded on a 1% agarose gel to compare the relative intensity of 28 S and 18 S ribosomal RNAs. Similar intensities were observed in all samples (data not shown). Polyadenylated RNAs were purified on oligo(deoxythymidine)-cellulose affinity columns (Pharmacia Biotech Inc.).

cDNA Isolation and Plasmid Constructions

Total liver RNA (5 µg) was transcribed into cDNA in a 20-µl reaction using 200 units of Moloney murine leukemia virus reverse transcriptase (RT) primed with 1 µg of oligo(deoxythymidine)12-18 primer (Boehringer Mannheim) and conditions described by the manufacturer (Life Technologies, Inc.). Half of each product was used as template for polymerase chain reaction (PCR) using primer pairs hGR5-hGR23 or hGR15-hGR3 specific for each part of the GH receptor (see Table I and Fig. 1A). The reaction was carried out in PCR buffer (50 mM KCl, 2 mM MgCl2, and 20 mM Tris-HCl, pH 8.3), 200 µM deoxy-NTPs, 25 pmol of forward and reverse primers, and 1 units of Taq polymerase (Perkin-Elmer) in a total volume of 50 µl. The experiment proceeded for 20 cycles, where a cycle consisted of 45 s at 94 °C, 1 min at 53 °C, and 1.5 min at 72 °C. After a 10-min final extension at 72 °C, the products were isolated on a 2% agarose gel, electroeluted, and subcloned into the pCRII vector (TA Cloning Kit, Invitrogen). After insert orientation, each part of the receptor cDNA subcloned was digested by KpnI (restriction enzyme site contained in the pCRII vector)-XbaI (restriction enzyme site contained in the insert), and introduced at the same time into the pECE expression vector previously digested with KpnI and treated with alkaline phosphatase. This construction contained the cDNA encoding the full-length monkey receptor. This cDNA was excised by BstXI digestion and subcloned in the pcDNA3 expression vector (Invitrogen). It consisted of 2131 bp with 104 bp in 5'-untranslated and 113 bp in 3'-untranslated regions, and an open reading frame of 1914 bp.

Table I. Oligonucleotides used for PCR cloning, RT/PCR, and Southern and Northern hybridization

Name, sequence, position (nucleotides), and the use of each oligonucleotide are indicated. Nucleotide positions of human primers can be found in Refs. 11 and 41. See "Experimental Procedures" and text for details.

Name Sequence Position Usage

nt
hGR3 5'-TAGAATCCATACCCCATCCTG-3' 2021 -2041 Cloning
hGR5 5'-TCTGCTTGCATATATGAGTGA-3" 127 -107 Cloning
hGR15 5'-TTTCCTTCCTTGAGGAGATCTGG-3' 931 -954 Cloning
hGR23 5'-CCCTATATTGACAACATCAGTTCC-3' 624 -647 Cloning
mGR0 5'-CTGCTGTTGACCTTGGCACTG-3' 16 -36 Cloning
mGR31 5'-GGACAGATGCGGTTCATCATGG-3' 203 -224 Cloning
mGR46 5'-TACCTCCGTCTGGATACCTTA-3' 354 -374 Southern
mGR56 5'-GTCCAGTTGAGGGCAATGG-3' 455 -473 Cloning
mGR73 5'-TCCTATATTGTCAACATCAGTTCC-3' 624 -647 Southern
mGR104 5'-CCTTCCTTGAGGAGATCTGG-3' 931 -950 Southern
TMD 5'-GCCCAAATATTCCAAAGATAATAATTAAGAGCC-3' 800 -832 Northern
mGbp 5'-GCTATTTTAATCTTTTATTTCTTTTACC-3' 784 -811 Southern
AP 5'-GGCCACGCGTCGACTAGTACTTTTTTTTTTT-3' Cloning
Y1 5'-CCGCGTCTCCTTTGAGCTGTTTGCAG-3' 54 -79 Southern
Y2 5'-ACCCAAAGGGAACTGCAGCGAGAGC-3' 598 -622 Southern


Fig. 1. Cloning, sequencing, Northern, and Southern strategies used to identify the monkey GH receptor. A, schematic representation of mkGHR mRNA derived from the nucleotide sequence of the two cDNAs inserts shown in B. 5'- and 3'-untranslated regions are represented by solid lines; coding region, enclosed box; signal peptide, black box; transmembrane domain, stippled box. The dotted lines at the ends represent as yet non-identified regions of mRNA. Positions of PCR primers and size of amplicons 5' and 3' (in base pairs) are indicated. B, the two cDNAs and the location of restriction fragments (E, extracellular; I, intracellular) and oligonucleotide (TMD) specific of the transmembrane domain, used as Northern hybridization probes. C, position of PCR primers: mGR46, mGR104; and nucleotide probe, mGR73, used for Southern blot.
[View Larger Version of this Image (10K GIF file)]

DNA Sequencing and Sequence Analysis

Double stranded DNA was sequenced by the dideoxy chain termination method (34) using modified T7 DNA polymerase (Sequenase, U. S. Biochemical Corp.) and by the PCR technique (Perkin-Elmer). Sequence comparisons were performed using the Bisance Program (35).

Cell Culture and Transfection

COS-7 cells were grown in minimal essential medium containing 10% fetal bovine serum (Life Technologies Inc.) on 6-well plates. Cells were transfected at 70% confluence (7 × 105 cells/well) by a modification of the DEAE-dextran-chloroquine procedure (36) with 1 µg of pcDNA3/mkGHR per well: the precipitate was made with 10 mg/ml DEAE-dextran, 100 µM chloroquine, and 10 ng of DNA/µl. After 4 h, the precipitate was removed, cells were subjected to 10% dimethyl sulfoxide shock for 2 min, and fresh medium was added. Twenty-four hours after transfection, the medium was replaced by GC 3 medium for 12 h and hGH binding was studied.

Human kidney fibroblast 293 cells were grown in Dulbecco's modified Eagle's medium nut F12 medium containing 10% fetal bovine serum. Several hours before transfection cells were plated in two-thirds Dulbecco's modified Eagle's medium nut F12, one-third Dulbecco's modified Eagle's medium 4.5 g/liter glucose medium containing 10% fetal bovine serum. For binding studies, the cells (5 × 105 cells/well of 6 wells plate) were transfected with 0.5 µg of pcDNA3/mkGHR or pcDNA3/mkGHBP cDNAs using the calcium phosphate technique. After 24 h of expression, cells were deprived of serum for an overnight period and hGH binding was studied. The conditioned medium was recovered for GHBP measurement.

For GH dependent induction of reporter construct, 293 cells were plated in 6-well plates before being transiently cotransfected as described before with 0.5 µg of pCH110 (beta -galactosidase expression vector from Pharmacia), 100 ng of plasmid pcDNA3/mkGHR, and 75 ng of the fusion gene construct containing the luciferase-coding sequence linked to either the sequence -175/59 of Spi 2.1 promoter (plasmid Spi-luc) or to 2.3 kb of the beta -casein promoter (plasmid beta -Cas-luc). One day after transfection, cells were incubated with serum-free medium containing 50 nM rhGH and 250 nM dexamethasone (Sigma) or 250 nM dexamethasone alone for 48 h. Cells were then lysed in lysis buffer (Pharmacia), and whole cell extracts were used for determination of luciferase and beta -galactosidase activities. To correct for differences in transfection efficiencies between plates within an experiment, luciferase activity was normalized to beta -galactosidase activity.

For purification of GHR complexes and Western blot analysis, 293 cells (5 × 106, in 100-mm dishes) were transfected with 4 µg of plasmid pcDNA3/mkGHR and 2 µg of cDNA encoding JAK2 (kindly provided by Dr. J. Ihle), according to the same protocol.

Immunoprecipitation and Western Blot Analysis

Transfected 293 cell extracts in 0.5 ml of lysis buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 5 mM EDTA, 1 mM sodium orthovanadate, 30 mM sodium pyrophosphate, 50 mM sodium fluoride, 1 mM phenylmethylsulfonyl fluoride, 5 µg/ml aprotinin, 2 µg/ml leupeptin, 1 µg/ml pepstatin, and 0.6% Triton X-100) were incubated with the designated antibody and with protein A-Sepharose (50%, v/v) under nondenaturating conditions, overnight at 4 °C. Immunoprecipitated complexes were washed three times in cold lysis buffer, boiled in SDS sample buffer, and subjected to 7% SDS-polyacrylamide gel electrophesis. Proteins were transferred onto a nitrocellulose filter and immunodetected with either an anti-phosphotyrosine antibody (4G10; Upstate Biotechnology, 0.1 mg/ml) or an anti-JAK2 antibody (Upstate Biotechnology, dilution 1/4000) overnight at 4 °C. The membranes were incubated with an anti-mouse or anti-rabbit antibody coupled to peroxidase for 1 h at room temperature before being washed four times for 30 min in washing buffer (50 mM Tris-HCl, pH 7.6, 200 mM NaCl, 0.05% Tween 20) and revealed by chemiluminescence (ECL kit from Amersham). Membranes were stripped overnight at 4 °C in an acid solution (0.1 M glycine, pH 3, 0.1 M NaCl) and reprobed.

Binding Studies

[125I]hGH was prepared using chloramine-T, as described previously (9), with a specific activity ranging between 80 and 180 µCi/µg.

Liver and kidney were cut into pieces and homogenized with an equal volume of 250 mM sucrose, buffered at pH 7.4 with 3 mM imidazole-HCl, using a Teflon-glass homogenizer. Microsomal membrane fractions were prepared by differential centrifugation (9). Incubation of [125I]hGH (1 × 10-10 M) with liver membrane fraction in a volume of 450 µl (25 mM Tris-HCl and 20 mM MgCl2, pH 7.4, with 0.1% bovine serum albumin) was performed for 18 h at 4 °C. Incubations were stopped by addition of 3 ml of chilled binding buffer. Bound and free hormones were separated by centrifugation at 3000 × g for 30 min.

Transfected COS-7 or 293 cells (1 × 106 cells/well of 6-well plates) were incubated with [125I]hGH in phosphate-buffered saline containing 0.5% bovine serum albumin. Incubations were carried out at room temperature for 4 h. Cells were washed twice with ice-cold phosphate-buffered saline; then cells were lysed by 1 ml of 1 N NaOH. Pellets and cell suspensions were counted using a LKB Pharmacia gamma -spectrometer.

Binding of [125I]hGH to serum GHBP was measured by gel filtration and high performance liquid chromatography, as described previously (37). For cells in culture, media were concentrated (20 times) using Centriprep 30 column (Amicon). Scatchard analyses were performed using the Ligand program (38).

Northern Blot Analysis

Ten to twenty µg of polyadenylated RNA were electrophoresed through a 1.1% agarose, 2.2 M formaldehyde gel and transferred to Hybond-N+ membrane (Amersham) by capillary blotting under high ionic strength in 20 × standard saline citrate (1 × SSC, 0.15 M NaCl, and 0.015 M sodium citrate, pH 7.2). Membranes were baked at 80 °C for 2 h and prehybridized for 4 h at 65 °C in 1% bovine serum albumin, 1 mM EDTA, 0.5 M NaHPO4, pH 7.2, 7% SDS (39), and 100 mg/ml denatured salmon sperm DNA. The membranes were then hybridized overnight at 65 °C in the prehybridization buffer in the presence of 106 cpm/ml 32P-labeled cDNA probe, previously denatured for 5 min at 100 °C. Washes were performed at 65 °C once in 1 × SSC, 0.1% SDS and then twice in 0.1 × SSC, 0.1% SDS, 30 min each. Autoradiographic exposure was about 1 week at -80 °C with intensifying screen. The membranes were stripped and reprobed with the given probe (E, I, and TMD, Fig. 1B) and the human cyclophilin cDNA probe was used as control (40). Probe E corresponds to the first 813 bp of the receptor extracellular part and was obtained by digestion of the 5' PCR fragment with EcoRI and XbaI. Probe I correspond to a 670-bp part of the receptor intracellular domain and was obtained by digestion of the 3' PCR fragment with EcoRI and HindIII. The TMD probe is a 33-mer oligonucleotide specific for the transmembrane region of the receptor (Table I); the GHBP probe is a 28-mer reverse oligonucleotide corresponding to the specific sequence of the mGbp (Table I) and was 5'-end-labeled.

RT-PCR and Southern Blot Analysis

cDNA synthesis and PCR amplification were carried out as described before. Four different sets of primers were used mGR46-mGR104, mGR0-mGR56, mGR0-mGR104, and mGR46-mGbp (Table I, Fig. 1B) and the annealing temperature used for 25 PCR cycles was 54 °C. The amplification products were separated on 2.2% agarose gel, stained with ethidium bromide, and transferred onto a Hybond N+ membrane (Amersham). Southern hybridization with a 5'-end-labeled oligonucleotide probe mGR73 was performed according to the manufacturer's instructions. To control the efficiency of the reverse transcription reaction, a control amplification of the ubiquitous protein cyclophilin (40) was performed on the same sample using specific human primers Y1 and Y2 (Table I).

3'-RACE-PCR Cloning

Total kidney and heart RNA (4 µg) were transcribed into cDNA using the 3'-RACE system for rapid amplification of cDNA ends and conditions described by the manufacturer (Life Technologies, Inc.). 5 µl of each product were used as template for PCR amplification as described previously using primers mGR0 and AP (Table I). The experiment proceeded for 30 cycles, where a cycle consisted of 35 s at 94 °C, 1.30 min at 63 °C, and 3 min at 72 °C. The products were diluted 1/50 and submitted to a second amplification for 25 cycles, with an annealing temperature of 68 °C using primers mGR31 and AP (Table I). After a 15-min final extension at 72 °C, the products were isolated on a 2% agarose gel, electroeluted, and subcloned into the pMOS Blue cloning vector (Amersham). The insert was sequenced and oriented; to construct an expression vector containing cDNA encoding the mkGHBP, this specific sequence was introduced in pcDNA3/mkGHR plasmid as a substitute for the transmembrane and cytoplasmic domains.


RESULTS

Binding Characteristics of the Monkey GHR

The specific binding of [125I]hGH to microsomal membrane fractions from two male Rhesus macaque livers was similar: 3.5 and 4.9% of total radioactivity/300 µg of membrane protein. A microsomal fraction prepared from kidney of the same two animals had a very low level of binding, less than 1%. Binding affinities to liver GHR were 1.95 ± 0.08 × 109 M-1 and 3.31 ± 0.16 × 109 M-1, with a comparable binding capacity of 26.37 ± 0.58 and 23.27 ± 0.51 fmol/mg protein, respectively.

Cloning, Sequencing, and Characterization of Monkey GHR cDNA

The cDNA of the monkey GHR was cloned in two parts, hGR5-hGR23 called 5' and hGR15-hGR3 called 3', with the common hGR15-hGR23 region (Fig. 1). These two parts had a size of 1087 and 1389 bp, respectively. The hGR5 and hGR3 primers were chosen with regard to the sequence alignment in the 5'- and 3'-untranslated regions that are conserved over species (Table I). To confirm the sequence obtained by PCR amplification of two long fragments, amplification of given portions of the sequence was performed using specific pairs of primers mGR0-mGR56 and mGR46-mGR104 (Table I). The sequences obtained were identical using the two methods. The overall amino acid identity is 94.1% with the human GH receptor, and all the characteristic domains of GHR family are conserved.

COS-7 cells were transiently transfected with the cDNA of the full-length receptor inserted in the pcDNA3 eucaryotic expression vector. Specific binding of [125I]hGH to whole cells demonstrated that the cloned receptor was expressed by the transfected cells. The association constant calculated by Scatchard analysis from the competition experiment shown in Fig. 2 was 5.75 ± 0.16 × 109 M-1 and the binding capacity was of 22,000 sites/cell. Scatchard analysis from competition binding was also performed with 293 cells transiently transfected with the mkGHR cDNA; the affinity constant was the same, 4.35 ± 0.11 × 109 M-1.


Fig. 2. Competition binding of [125I]hGH to COS cells transfected with mkGHR cDNA. Cells were incubated in the presence of labeled ligand and various concentrations of unlabeled hormones, human (bullet ), bovine (open circle ) GH, and human PRL (black-square). The results are expressed as percentage of the maximal binding observed in the absence of competitor (32% of the total radioactivity added).
[View Larger Version of this Image (14K GIF file)]

As expected for a primate GH receptor, recombinant bovine GH failed to compete with [125I]hGH; a small effect could be observed only at high concentrations of unlabeled hormone demonstrating the specificity of this primate receptor for primate GH (Fig. 2). Somatogenic specificity was also attested by absence of competition by recombinant human PRL with [125I]hGH binding (Fig. 2).

Functional Studies of the Monkey GHR

We have used the constructs beta -casein/luciferase (beta -Cas-luc) or Spi 2.1/luciferase (Spi-luc) to test the ability of GH to activate beta -casein or serine protease inhibitor gene transcription. Human 293 fibroblast cells were transiently cotransfected with a plasmid containing the mkGHR (in pcDNA3 vector) and reporter gene constructs (beta -Cas-luc or Spi-luc). These cotransfections resulted in a clearly inducible luciferase activity by GH. The maximal effect could be achieved with 50 nM hGH, as described previously (16).2 Maximal fold induction is 6.2 ± 0.6 for the beta -Cas-luc construction and 4.1 ± 0.5 for the Spi-luc.

The association between monkey GHR and JAK2 kinase was studied in 293 cells transiently cotransfected with mkGHR and JAK2 cDNA. The phosphorylation of both JAK2 kinase and GHR is stimulated by hGH. As shown in Fig. 3A, the stimulation of the phosphorylation is about 8-fold for GHR and 2.2-fold for JAK2. Fig. 3B confirms that the same quantity of protein was loaded on lanes corresponding to stimulated and unstimulated cells following immunoprecipitation by anti-JAK2 and anti-GHR. A 2.5-fold induction of JAK2 is also seen after immunoprecipitation by anti-phosphotyrosine following GH stimulation (Fig. 3B). Basal phosphorylation of GHR and especially of JAK2 is detectable as shown in Fig. 3A, in lanes (GH), using anti-JAK2 and anti-GHR antibodies, suggesting a constitutive association of JAK2 with GHR. Also, in the absence of GH stimulation, a complex containing the GHR and JAK2 is immunoprecipitated by the anti-receptor mAb 263 (Fig. 3B). Interestingly, this association does not appear to be modified by GH stimulation. In fact, stimulation by GH results in induction of tyrosine phosphorylation of JAK2 and the GHR but there is no further recruitment of JAK2 by the activated receptor.


Fig. 3. Tyrosine-phosphorylated proteins in 293 cells cotransfected with mkGHR and JAK2 cDNAs. Cells were stimulated (+) or not (-) with 50 nM hGH for 5 min. Whole cell lysates were immunoprecipitated with either anti-receptor mAb 263 (GHR), alpha JAK2, or alpha -Tyr(P) and analyzed by Western blot with alpha -Tyr(P) (A) or alpha JAK2 (B). The molecular weight of the protein standards are indicated on the right. The arrow on the left indicates the migration of JAK2 and GH receptor.
[View Larger Version of this Image (47K GIF file)]

Detection of GHBP in Monkey Serum and Culture Medium of Cells Expressing the Monkey GHR

The elution profile of [125I]hGH incubated with serum obtained from an adult Macaque is shown in Fig. 4A. A single peak is observed at the elution time expected for GHBP (37). An excess of unlabeled hGH inhibited this peak demonstrating the specificity of the hGH binding. In 12 different sera, the specific binding ranged from 2.1 to 11.0% of total radioactivity (for 100 µl of serum). Recombinant bovine GH and human PRL had no effect on the binding of [125I]hGH to the GHBP, demonstrating that it is a primate GH-binding protein without lactogenic specificity (data not shown).


Fig. 4. Gel filtration profiles of [125I]hGH incubated with adult monkey serum (A), with culture medium of monkey GHR cDNA transfected cells (B), or with culture medium of monkey GHBP cDNA transfected cells (C). Incubations were performed in the absence (thick lines) and presence of 5 µg of hGH (thin line). The elution time of complexed [125I]hGH-GHBP (peak I) was 17 min, and 22 min for [125I]hGH (peak II).
[View Larger Version of this Image (14K GIF file)]

In the culture medium of 293 cells transiently expressing monkey GHR, the presence of the soluble receptor was also detected (Fig. 4B), with a comparable elution profile to that obtained with serum. The level of GH binding was 23% using concentrated culture medium (× 20). Scatchard analysis from competition binding showed an affinity constant of 2.0 ± 0.6 × 108 M-1 for the GHBP produced by proteolytic cleavage. No soluble GHR can be detected in culture medium of non-transfected 293 cells.

Gene Expression of the Monkey GHR

Northern blot analysis was performed to determine the size and the distribution of the GHR transcripts in various monkey tissues. A major transcript with an estimated size of 5.0 kb hybridized to probe E (Fig. 1B), in liver, heart, kidney, pancreas, intestine, stomach, muscle, and fat. Two other mRNAs were detected: one of ~2.8 kb in liver, kidney, and adipose tissue; another one of 1.7 kb was detected in heart, kidney, and stomach. In the stomach, the intensity of the signal of the 1.7-kb transcript was comparable to that of the 5.0-kb mRNA (Fig. 5A).


Fig. 5. Northern blot analyses of GH receptor mRNA in different monkey tissues. Ten to twenty micrograms of polyadenylated RNA from each tissue were electrophoresed, transferred on nitrocellulose membrane, and hybridized with a 32P-labeled cDNA probe E coding for part of the extracellular domain of GHR (A) or with probe I coding for part of the intracellular domain or TMD oligonucleotide corresponding to the transmembrane domain (B). C, control hybridization the the human cyclophilin cDNA probe. Autoradiography after 8 days of exposure with intensifying screen at -80 °C.
[View Larger Version of this Image (59K GIF file)]

To look for differences in the coding region, the same membranes were hybridized with probe I (Fig. 1B) which is specific for the cytoplasmic domain of the receptor. This probe hybridized with the two large mRNAs of 5.0 and 2.8 kb, but not with the 1.7-kb transcript (Fig. 5B). Using an oligonucleotide probe specific for the transmembrane domain, TMD primer (Table I), the hybridization profile is similar (data not shown). Hybridization of all membranes with a cyclophilin cDNA probe was also performed to normalize the results (Fig. 5C). As observed in all other species the liver showed the highest expression level of the long form; the expression of GHR mRNA was also high in heart, kidney, and adipose tissue.

We used RT-PCR with forward primer mGR46 and reverse primer mGR104, which spans a part of the extracellular coding region, the transmembrane domain, and a part of the intracellular region of the monkey GHR cDNA (Table I, Fig. 1B), to investigate GHR gene expression in various tissues. Ethidium bromide staining of amplified products separated on agarose gel showed in all tissue samples a band of the predicted length, 600 bp (Fig. 6A). The specificity of the amplification was confirmed by Southern hybridization using an internal probe, oligonucleotide mGR73 (Fig. 6B). The efficiency of the RT-PCR reaction was confirmed by a control amplification of the ubiquitous protein cyclophilin, using human primers (Fig. 6C).


Fig. 6. RT-PCR amplification of GHR mRNA in different monkey tissues. A, ethidium bromide staining of PCR products using mGR46 and mGR104 primers. B, hybridization of the gels shown in A after transfer using an internal probe (mGR73). C, ethidium bromide staining of PCR products using Y1 and Y2 primers of ubiquitous cyclophilin. The size of amplicons are indicated on the right in base pairs.
[View Larger Version of this Image (43K GIF file)]

During the analysis of the expression of GHR gene in monkey tissues, at least two additional bands were detected using RT-PCR with primer mGR0-mGR104. These products visualized by ethidium bromide staining showed one band with the expected size and two other smaller bands (data not shown). We subsequently purified each band, subcloned, and identified the sequence of these additional PCR products. The first clone we characterized resulted from an alternative splicing of exon 3 and corresponded to the human GHRd3 isoform (41, 42). It was observed in the different monkey tissues studied. The second clone was also a deletion mutant lacking exons 4, 5, and 6. This deletion resulted in a frameshift and introduced a stop codon in exon 7, before the region encoding the transmembrane domain. The putative protein product would be a secreted form of mkGHR of 44 amino acids.

Molecular Cloning of a cDNA Encoding a Putative GHBP

To further establish the existence of a specific transcript for the GHBP in monkey we used 3'-RACE-PCR to identify a specific sequence for a GHBP. Two subsequent amplifications performed on heart and kidney cDNA using upstream primers mGR0 and mGR31, respectively, gave a 250-bp cDNA fragment that was subcloned in the pcDNA3/mkGHR plasmid by substituting the transmembrane and cytoplasmic domains. The analysis of this sequence relative to the genomic sequence of the human GHR gene shows that this cDNA could be generated by a lack of splicing between exon 7 and intron 7. Thus, 236 bp of intron 7 are integrated in the coding sequence of the GHBP resulting in the addition of 8 new amino acids and a stop codon (Fig. 7). The 3' noncoding sequence includes an additional poly(A) signal followed by a poly(A) tract. This alternatively spliced mRNA would permit the production of a secreted extracellular domain of the GHR.


Fig. 7. Alternative splicing mechanism generating mkGHR and mkGHBP. Diagrammatic representation of the genomic DNA fragment involved in the generation of mkGHR and mkGHBP transcripts. Intron and exon sequences are denoted by shaded lowercase letters and boxed uppercase letters, respectively. Resulting amino acid sequences are shown above and below. Boldface lowercase letters indicate the intronic nucleic acids involved in the sequence of the GHBP. The extracellular domain-transmembrane junction is marked by an asterisk in the amino acid sequence.
[View Larger Version of this Image (13K GIF file)]

Fig. 4C shows the elution profile of culture medium of 293 cells transiently transfected with the pcDNA3/mkGHBP construct incubated with [125I]hGH. The secreted mkGHBP had an affinity constant of 2.94 ± 0.36 × 108 M-1, a value similar to that of the GHBP produced by proteolytic cleavage of the membrane bound receptor.

Using forward primer mGR46 and reverse primer mGbp (Table I), we investigated the expression of this putative GHBP mRNA in 6 different tissues. Ethidium bromide staining of amplified products separated on agarose gel showed a band of the predicted length, 468 bp (Fig. 8A). The specificity of the amplification was confirmed by Southern hybridization using an internal probe, oligonucleotide mGR56 (Fig. 8B). The amplicon is present in kidney, heart, and is very abundant in stomach as expected from Northern blot analysis, but it is also detectable in the liver; in intestine and pancreas no signal could be observed.


Fig. 8. RT/PCR amplification of GHBP mRNA in different monkey tissues. A, ethidium bromide staining of PCR products using mGR46 and mGbp primers. B, hybridization of the gels shown in A after transfer using an internal probe, mGR56 primer. The size of amplicons are indicated on the right in base pairs.
[View Larger Version of this Image (43K GIF file)]


DISCUSSION

We have used RT-PCR with primers prepared from highly conserved regions of mammalian GH receptors to clone the cDNA of the Macaque rhesus GH receptor. Using several tests we demonstrate that this cDNA encodes a receptor protein which presents the expected specificity for a primate GHR and is fully functional. The monkey GHR gene is expressed not only in the liver, but in all the tissues analyzed. A 5.0- and 2.8-kb transcripts were detected with different probes and likely encode the full-length membrane receptor. In some tissues, another mRNA of 1.7 kb is seen that could result from alternative splicing and encode a GHBP. Using 3'-RACE-PCR we identified a cDNA encoding a GHBP that has been characterized.

The cDNA of the monkey GHR was constructed using two fragments of PCR of 1.0-1.4 kb to limit the amplification errors observed for long size fragments. The sequence obtained was also confirmed by amplification and sequencing of smaller fragments. Assembling, subcloning into eucaryotic expression vectors, and propagating the cDNA encoding the full-length monkey GHR in E. coli was successfully achieved. We were also able to express these constructs in eucaryotic cells to produce the expected fully active receptor. It is important to note that propagation in bacteria and also transfection of full-length human GHR cDNA with all the expected characteristics has proven difficult (3, 11), although recently, modifications in nucleotide sequences in and around the transmembrane region have permitted some amelioration (43).

The analysis of the mkGHR cDNA shows that it encodes a precursor protein of 638 amino acids which has a very high degree of identity with the human GHR (94.1%). Comparing the sequence of the hormones, human and monkey GH share 96.0% identity (29), a value similar to that for the GH receptor: this supports the hypothesis of a co-evolution of hormone and receptor in different species. Thus, the structure of human and monkey GHRs are probably very similar.

The functional activity of the receptor encoded by this cloned cDNA has been established. Expression of the monkey cDNA in COS cells results in a receptor protein with all the characteristics of a primate GHR. This receptor is able to bind hGH with an affinity similar to that found for the receptor present in monkey liver membranes. Moreover, this receptor is specific for hGH and is unable to bind nonprimate GH; it has somatogenic specificity and is devoid of lactogenic specificity. We also performed functional studies in 293 cells using the promoters of genes encoding beta -casein and Spi 2.1 in bioassays based on specific activation by GH as described previously (16, 17).2 Our findings demonstrate that beta -casein, specific for a lactogenic effect, and Spi 2.1 promoters are inducible by hGH in 293 cells transfected with the mkGHR cDNA. The fold induction obtained with the monkey GHR is similar to or greater than that obtained with the rat (16) or rabbit GHR cDNA (17).

To further establish the functional activity of this receptor, we investigated its signal transduction pathways. Binding of GH to cell surface receptors is the initial step of hormone action. An early event that occurs following hormone binding and homodimerization of the GHR (14, 44) is the rapid induction of tyrosine phosphorylation of several proteins, one of which has been identified as the tyrosine kinase JAK2 (15, 45). We have examined the association and the activation of tyrosine kinase JAK2, using the transient cotransfection system of both JAK2 and mkGHR cDNAs in 293 cell line. The fact that JAK2 and the receptor are phosphorylated even in the absence of GH stimulation could be due to autoactivation because of overexpression; and/or reveal a state of basal phosphorylation, amplified by the high copy number. Ours studies demonstrate that the monkey GHR is able to associate with JAK2 and to activate its phosphorylation; we also observed GHR tyrosine phosphorylation following GH stimulation. Both the internal deleted form of PRL receptor found in the Nb2 cell line and the long form of the rat PRL receptor were shown to be constitutively associated with the tyrosine kinase JAK2 (46-48), through the conserved proline-rich region, Box 1 (47, 49). In contrast to other models (17), the monkey GHR appears to be constitutively associated with JAK2 and stimulation by GH increases the level of tyrosine phosphorylation of both JAK2 and the GHR, but does not appear to promote the recruitment of JAK2 molecules.

Even if the biological functions of the GHBP remain to be clarified, it is of major interest to understand the mechanisms by which this protein is generated. GHBP is present in the serum of many species (50), and also in monkey serum. The binding affinity of the monkey GHBP is lower than the membrane R, as previously reported in human serum GHBP (9, 10). In our study, GHBP is detected in culture medium of cells transiently transfected with the monkey GHR full-length cDNA, suggesting that the GHBP measured in the serum of animals could be generated by proteolytic cleavage of the membrane receptor as demonstrated for rabbit GHR (27).

The expression pattern of the monkey GHR gene was studied. In man, GH receptor gene expression has been detected in many different tissues (12, 13), although the level of mRNA in nonhepatic tissues tends to be low and difficult to detect. In Northern blot analyses, large amounts of polyadenylated mRNA were required to detect the presence of transcripts, supporting the fact that GHRs are expressed in low abundance. Analysis of RT-PCR products revealed the widespread distribution of monkey GHR gene expression; as expected, mRNA were detected in all tissues tested, in gastrointestinal tract, muscle, spleen, kidney, and adipose tissue but with variations in the level of expression.

In the course of this study, we isolated and characterized two isoforms of the monkey GHR that have a deletion in the extracellular domain. These isoforms are thought to be generated by alternative splicing, since they specifically lack one or three exons. Such isoforms generated by alternative splicing have also been reported for the human PRLR (51). The GHR isoforms were detected in many different tissues and may have a general biological importance. The first one corresponds to the human GHRd3 isoform; the protein product of this GHR has been shown to be expressed on the cell surface and is capable of binding GH with the same affinity as the wild type (41). The other clone lacking exons 4, 5, and 6, would encode a secreted protein lacking GH binding activity.

Interestingly, different forms of monkey GHR mRNAs have been characterized by Northern blot analyses. The 5.0- and 2.8-kb transcripts are of sufficient size to encode the full-length membrane receptor, and they hybridize to both extra and intracellular probes and to an oligonucleotide specific to the transmembrane region. The different sizes could arise from multiple transcription starts or polyadenylation sites or from differential processing of a single transcript. The latter could affect either the coding region, the noncoding regions, or both. Furthermore, these sizes are consistent with the 4.5- and 2.8-kb transcripts reported in man (12). Also, a smaller mRNA of 1.7 kb, only detected with the extracellular probe, is expressed in stomach, heart, and kidney. In these three tissues of the two monkeys described, there was great variation in the level of expression of this mRNA, as well as in the relative expression of the 1.7-kb mRNA to the long form. The size of this transcript is not sufficient to encode the full-length receptor but is similar to the small mRNAs (1.2-1.5 kb) found in mouse and rat tissues and that had been demonstrated to encode the GHBP (24, 25). In man and rabbit, short forms of mRNA with an estimated size of 2.8 and 1.3 kb, respectively, were sometimes detected; but they have never been well characterized (12, 52).

3'-RACE-PCR allowed us to identify a specific monkey sequence for the GHBP. In fact, RT-PCR revealed that the expression of this transcript is specific to some tissues and its abundance is variable, highly expressed in stomach, heart, and kidney, less so in liver, and absent in some other tissues like intestine or pancreas. Thus, a local production of GHBP could occur in monkey and the nature of its tail is not directly related to that identified for the mouse or rat GHBP (24, 25). Recently, the presence of a splice variant of the GHR has been demonstrated in human tissues (53, 54). This mRNA results from a deletion in exon 9 leading to a stop codon at position 280. This short form of the membrane GHR could generate large amounts of GHBP. We were not able to find such a transcript capable of generating a GHBP in monkey tissues.

Taken together, these results demonstrate that the cloned cDNA expresses a fully functional GHR. The GHBP found in monkey serum could be generated through two separate mechanisms: proteolytic cleavage of the membrane receptor and a specific mRNA expressed in several monkey tissues. This is the first demonstration of a possible co-existence of the two mechanisms of GHBP generation within the same subject.


FOOTNOTES

*   This work was supported in part by the Institut National de la Santé et de la Recherche Médical and the Centre National d'Etudes Spatiales (C. N. E. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) U84589 (for the full-length receptor) and U85396 (for the binding protein).


Dagger    Recipient of a fellowship from the C. N. E. S. Present address: Department of Obstetrics, Gynecology & Reproductive Sciences, University of California, San Francisco, CA 94143-0556.
§   Contributed equally to the results in this paper and are considered co-first authors.
par    To whom correspondence should be addressed: INSERM U.344, Faculté de Médecine Necker-Enfants Malades, 156 rue de Vaugirard, 75730 Paris Cedex 15, France. Tel.: 33-1-40-61-53-10; Fax: 33-1-43-06-04-43.
1   The abbreviations used are: GH, growth hormone; GHR, GH receptor; GHBP, GH-binding protein; PRL, prolactin; PCR, polymerase chain reaction; RACE, rapid amplification of cDNA extremities; h, human; b, bovine; mk, monkey; kb, kilobase pair(s); bp, base pair(s); RT, reverse transcriptase.
2   H. Buteau, A. Pezet, P. A. Kelly, and M. Edery, manuscript in preparation.

ACKNOWLEDGEMENTS

We are grateful to Dr. J. Ihle for kindly providing the cDNA encoding the tyrosine kinase JAK2 and to H. Buteau for preparing the beta -casein/luciferase construct. We gratefully thank L. Sofer and F. Labaille for technical assistance.


REFERENCES

  1. Kelly, P. A., Djiane, J., Postel-Vinay, M. C., and Edery, M. (1991) Endocr. Rev. 12, 235-251 [Abstract]
  2. Billestrup, N., and Nielsen, J. H. (1991) Endocrinology 129, 883-888 [Abstract]
  3. Colosi, P., Wong, K., Leong, S. R., and Wood, W. I. (1993) J. Biol. Chem. 268, 12617-12623 [Abstract/Free Full Text]
  4. Goodman, H. M. (1981) Endocrinology 109, 120-129 [Abstract]
  5. Doglio, A., Dani, C., Grimaldi, P., and Ailhaud, G. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 1148-1152 [Abstract]
  6. Mathews, L. S., Norstedt, G., and Palmitter, R. D. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 9343-9347 [Abstract]
  7. Yoon, J.-B., Towle, H. C., and Seelig, S. (1987) J. Biol. Chem. 262, 4284-4289 [Abstract/Free Full Text]
  8. Shindler, C., and Darnell, J. E., Jr. (1995) Annu. Rev. Biochem. 64, 621-651 [CrossRef][Medline] [Order article via Infotrieve]
  9. Hocquette, J. F., Postel-Vinay, M. C., Kayser, C., de Hemptinne, B., and Amar-Costesec, A. (1989) Endocrinology 125, 2167-2174 [Abstract]
  10. Hocquette, J. F., Postel-Vinay, M. C., Djiane, J., Tar, A., and Kelly, P. A. (1990) Endocrinology 127, 1665-1672 [Abstract]
  11. Leung, D. W., Spencer, S. A., Cachianes, G., Hammonds, R. G., Collins, C., Henzel, W. J., Barnard, R., Waters, M. J., and Wood, W. I. (1987) Nature 330, 537-543 [CrossRef][Medline] [Order article via Infotrieve]
  12. Delehaye-Zervas, M. C., Mertani, H., Martini, J. F., Nihoul-Fekete, C., Morel, G., and Postel-Vinay, M. C (1994) J. Clin. Endocrinol. Metab. 78, 1473-1480 [Abstract]
  13. Mertani, H. C., Delehaye-Zervas, M. C., Martini, J. F., Postel-Vinay, M. C., and Morel, G. (1995) Endocrine 3, 135-142
  14. Cunningham, B. C., Ultsch, M., De Vos, A. M., Mulkerrin, M. G., Clauser, K. R., and Wells, J. A. (1991) Science 254, 821-825 [Medline] [Order article via Infotrieve]
  15. Argetsinger, L. S., Campbell, G. S., Wang, X., Witthuhn, B. A., Silvennoinen, O., Ihle, J. N., and Carter-Su, C. (1993) Cell 74, 237-244 [Medline] [Order article via Infotrieve]
  16. Goujon, L., Allevato, G., Simonin, G., Paquereau, L., Le Cam, A., Clark, J., Nielsen, J. H., Djiane, J., Postel-Vinay, M. C., Edery, M., and Kelly, P. A. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 957-961 [Abstract]
  17. Sotiropoulos, A., Perrot-Applanat, M., Dinerstein, H., Pallier, A., Postel-Vinay, M. C., Finidori, J., and Kelly, P. A. (1994) Endocrinology 135, 1292-1298 [Abstract]
  18. Moller, C., Hansson, A., Enberg, B., Lobie, P. E., and Norstedt, G. (1992) J. Biol. Chem. 267, 23403-23408 [Abstract/Free Full Text]
  19. Gronowski, A. M., and Rotwein, P. (1994) J. Biol. Chem. 269, 7874-7878 [Abstract/Free Full Text]
  20. Billestrup, N., Bouchelouche, P., Allevato, G., Ilondo, M., and Nielsen, J. H. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 2725-2729 [Abstract]
  21. Baumann, G., Stolar, M. W., Amburn, K., Barsano, C. P., and DeVries, B. C. (1986) J. Clin. Endocrinol. Metab. 62, 134-141 [Abstract]
  22. Herington, A. C., Ymer, S., and Stevenson, J. (1986) J. Clin. Invest. 77, 1817-1823 [Medline] [Order article via Infotrieve]
  23. Spencer, S. A., Hammonds, R. G., Henzel, W. J., Rodriguez, H., Waters, M. J., and Wood, W. I. (1988) J. Biol. Chem. 263, 7862-7867 [Abstract/Free Full Text]
  24. Smith, W. C., Kuniyoshi, J., and Talamantes, F. (1989) Mol. Endocrinol. 3, 984-990 [Abstract]
  25. Baumbach, W. R., Horner, D. I., and Logan, J. S. (1989) Genes Dev. 3, 1199-1205 [Abstract]
  26. Trivedi, B., and Daughaday, W. H. (1988) Endocrinology 123, 2201-2206 [Abstract]
  27. Sotiropoulos, A., Goujon, L., Simonin, G., Kelly, P. A., Postel-Vinay, M. C., and Finidori, J. (1993) Endocrinology 132, 1863-1865 [Abstract]
  28. Li, C. H., and Papkoff, H. (1956) Science 124, 1293-1294 [Medline] [Order article via Infotrieve]
  29. Li, C., Chung, D., Lahm, H. W., and Stein, S. (1986) Arch. Biochem. Biophys. 245, 287-291 [Medline] [Order article via Infotrieve]
  30. Golos, T. G., Durning, M., Fisher, J. M., and Fowler, P. D. (1993) Endocrinology 33, 1744-1752
  31. Posner, B. I., Kelly, P. A., Shiu, P. C., and Friesen, H. G. (1974) Endocrinology 95, 521-531 [Medline] [Order article via Infotrieve]
  32. Mann, D. R., Rudman, C. G., Akinbami, M. A., and Gould, K. G. (1992) J. Clin. Endocrinol. Metab. 74, 1263-1269 [Abstract]
  33. Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156-159 [CrossRef][Medline] [Order article via Infotrieve]
  34. Sanger, F., Nicklen, S., and Conlson, A. R. (1977) Proc. Natl. Acad. Sci. U. S. A. 74, 5463-5467 [Abstract]
  35. Dessen, P., Fondrat, C., Valencien, C., and Mugnier, C. (1990) Comput. Appl. Biosci. 6, 355-356 [Medline] [Order article via Infotrieve]
  36. McCutchan, J. H., and Pegano, J. S. (1968) J. Natl. Cancer Inst. 41, 351-357 [Medline] [Order article via Infotrieve]
  37. Tar, A., Hocquette, J. F., Souberbielle, J. C., Clot, J. P., Brauner, R., and Postel-Vinay, M. C. (1990) J. Clin. Endocrinol. Metab. 71, 1202-1207 [Abstract]
  38. Munson, P. J., and Rodbard, O. (1980) Anal. Biochem. 107, 220 [Medline] [Order article via Infotrieve]
  39. Church, G. M., and Gilbert, W. (1983) Proc. Natl. Acad. Sci. U. S. A. 81, 1991-1995
  40. Haendler, B., Hofer-Warbinek, R., and Hofer, E. (1987) EMBO J. 6, 947-950 [Abstract]
  41. Urbanek, M., MacLeod, J. N., Cooke, N. E., and Liebhaber, S. A. (1992) Mol. Endocrinol. 6, 279-287 [Abstract]
  42. Mercado, M., Davila, N., McLeod, J. N., and Baumann, G. (1994) J. Clin. Endocrinol. Metab. 78, 731-735 [Abstract]
  43. Wang, Y. D., and Wood, W. I. (1995) Mol. Endocrinol. 9, 303-311 [Abstract]
  44. De Vos, A. M., Ultsch, M., and Kossiakoff, A. A. (1992) Science 255, 306-312 [Medline] [Order article via Infotrieve]
  45. Wang, X., Moller, C., Norstedt, G., and Carter-Su, C. (1993) J. Biol. Chem. 268, 3573-3579 [Abstract/Free Full Text]
  46. Rui, H., Kirken, R. A., and Farrar, W. L. (1994) J. Biol. Chem. 269, 5364-5368 [Abstract/Free Full Text]
  47. Lebrun, J.-J., Ali, S., Sofer, L., Ullrich, A., and Kelly, P. A. (1994) J. Biol. Chem. 269, 14021-14026 [Abstract/Free Full Text]
  48. Campbell, G. S., Argetsinger, L. S., Ihle, J. N., Kelly, P. A., Rillema, J. A., and Carter-Su, C. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 5232-5236 [Abstract]
  49. Edery, M., Levi-Meyrueis, C., Paly, J., Kelly, P. A., and Djiane, J. (1994) Mol. Cell. Endocrinol. 102, 39-44 [CrossRef][Medline] [Order article via Infotrieve]
  50. Baumann, G. (1991) Endocr. Rev. 12, 424-449 [Abstract]
  51. Nagano, M., Chastre, E., Choquet, A., Bara, J., Gespach, C., and Kelly, P. A. (1995) Am. J. Physiol. 268, G431-G442 [Abstract/Free Full Text]
  52. Tiong, T. S., Freed, K. A., and Herington, A. C. (1989) Biochem. Biophys. Res. Commun. 158, 141-148 [Medline] [Order article via Infotrieve]
  53. Ross, R. J. M., Esposito, N., Shen, X. Y., Von Laue, S., Chew, S. L., Postel-Vinay, M. C., and Finidori, J. (1997) Mol. Endocrinol. 11, 265-273 [Abstract/Free Full Text]
  54. Dastot, F., Sobrier, M. L., Duquesnoy, P., Duriez, B., Goossens, M., and Amselem, S. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 10723-10728 [Abstract/Free Full Text]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.